Emcure Pharma Q4FY25 Earnings Results: Revenue and PAT Recorded Double-Digit Growth

On May 23, 2025, Emcure Pharma share price locked in 10% upper circuit at ₹1,288.65 on BSE, following the previous day's gain of over 9%. The gain in the Emcure Pharma share price follows the release of Q4FY25 and FY25 earnings. Emcure Pharmaceuticals delivered a robust financial performance in the Q4FY25, posting a 63% year-on-year (YoY) increase in consolidated net profit, which rose to ₹197.2 crore from ₹121 crore in Q4FY24.

Operational revenue also saw solid growth, climbing 19.5% to ₹2,116.2 crore compared to ₹1,771.3 crore in the same quarter last year.

On a sequential basis, Emcure’s net profit rose by 26.4% from ₹156 crore in Q3FY25, while revenue from operations increased by 7.8% from ₹1,936 crore. The company attributed its strong quarterly performance to a well-rounded contribution from both domestic and international markets.

Domestic Business Growth

Emcure’s domestic operations recorded a 24.8% YoY increase in revenue, reaching ₹929 crore. This growth was primarily fueled by strong momentum in its women’s health and cardiology divisions, further supported by expanding efforts in dermatology and over-the-counter (OTC) product segments, the company stated in a regulatory filing.

International Performance

On the international front, revenue rose by 15.6% YoY to ₹1,187 crore in Q4FY25, up from ₹1,027 crore in the corresponding quarter of the previous fiscal. Notably, the "Rest of the World" segment witnessed a remarkable 39.3% surge, generating ₹481 crore compared to ₹345 crore in Q4FY24.

The Canadian market contributed ₹310 crore, marking a 6.2% YoY rise from ₹293 crore, while the European Union business grew modestly by 1.7%.

Emcure Dividend Announcement

The Board of Directors has recommended a final dividend of ₹3 per equity share (face value of ₹10 each), translating to a 30% payout for the financial year ending March 31, 2025.

Also Read: Best Pharma Stocks in India for May 2025

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure delivered a very strong performance in Q4 with all our business segments contributing to growth. Over the past year, we have effectively executed our strategies across both Domestic and International markets. On the Domestic side, we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets, we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.